Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt

DUBLIN , June 29, 2018 /PRNewswire/ —┬á Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a definitive agreement to sell its rights related to Prialt┬« (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in cash at closing.